January 12, 2017 09:54 AM ESTUpdated January 17, 09:49 AM
News Briefing

Bio­gen spin­off be­gins trad­ing to­day; New on­col­o­gy chief at As­traZeneca

Shehla Shakoor

Managing Director

• Shares of Bio­gen’s he­mo­phil­ia spin­off Biover­a­tiv be­gan trad­ing to­day on a “when is­sued” ba­sis and will be­gin reg­u­lar trad­ing on Feb­ru­ary 2nd un­der …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Lil­ly's board un­der­goes more changes; Mer­ck strat­e­gy chief joins Roger Perl­mut­ter at Eikon

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs 

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

From vac­cines to psy­che­delics, five drug­mak­ers on what could change un­der a Trump ad­min­is­tra­tion

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times